1. Home
  2. SIG vs TLX Comparison

SIG vs TLX Comparison

Compare SIG & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Signet Jewelers Limited

SIG

Signet Jewelers Limited

N/A

Current Price

$100.26

Market Cap

3.4B

ML Signal

N/A

Logo Telix Pharmaceuticals Limited American Depositary Shares

TLX

Telix Pharmaceuticals Limited American Depositary Shares

N/A

Current Price

$11.29

Market Cap

3.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SIG
TLX
Founded
1950
2015
Country
Bermuda
Australia
Employees
N/A
N/A
Industry
Consumer Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4B
3.9B
IPO Year
1997
2024

Fundamental Metrics

Financial Performance
Metric
SIG
TLX
Price
$100.26
$11.29
Analyst Decision
Buy
Strong Buy
Analyst Count
7
4
Target Price
$111.14
$21.13
AVG Volume (30 Days)
754.3K
155.5K
Earning Date
06-02-2026
08-19-2026
Dividend Yield
1.65%
N/A
EPS Growth
974.07
N/A
EPS
2.11
N/A
Revenue
$6,247,100,000.00
N/A
Revenue This Year
$1.39
N/A
Revenue Next Year
$1.71
N/A
P/E Ratio
$131.29
$150.33
Revenue Growth
N/A
N/A
52 Week Low
$71.62
$6.28
52 Week High
$110.20
$12.48

Technical Indicators

Market Signals
Indicator
SIG
TLX
Relative Strength Index (RSI) 64.07 55.50
Support Level $80.87 $10.12
Resistance Level $100.46 $12.35
Average True Range (ATR) 3.47 0.25
MACD 1.85 0.04
Stochastic Oscillator 77.54 66.96

Price Performance

Historical Comparison
SIG
TLX

About SIG Signet Jewelers Limited

Signet Jewelers Ltd is a retailer of diamond jewelry. Its merchandise mix includes bridal, fashion, watches, and others. The bridal category includes engagement, wedding, and anniversary purchases. Its segments are the North America segment, the International segment, and the Other segment. The North America segment contributes to the majority of the revenue. The North America segment generates revenue from Mall and Outlet. Geographically, it operates in the USA, Canada, the UK, and Ireland, with the maximum revenue from the USA.

About TLX Telix Pharmaceuticals Limited American Depositary Shares

Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.

Share on Social Networks: